Mode
Text Size
Log in / Sign up
Phase 3 N=417 Randomized Triple-blind Treatment

BOTOX® in the Treatment of Crow's Feet Lines in China

Lateral Canthal Lines · Crow's Feet Lines

Enrolled (actual)
417
Serious AEs
0.0%
Results posted
Mar 2016
Primary outcome: Primary: Percentage of Subjects Achieving None or Mild on the Investigator's Assessment of the Severity of Crow's Feet Lines (CFL) at Maximum Smile Using the Facial Wrinkle Scale-Asian (FWS-A) — 63.9; 5.0 Percentage of Subjects

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
botulinum toxin Type A (Biological); Normal Saline (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Allergan
Primary completion
Feb 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Subjects Achieving None or Mild on the Investigator's Assessment of the Severity of Crow's Feet Lines (CFL) at Maximum Smile Using the Facial Wrinkle Scale-Asian (FWS-A)
63.9; 5.0
SECONDARY
Percentage of Subjects With a ≥ 1-grade Improvement on the Investigator's Assessment of CFL Severity at Rest Using the 4-point FWS-A
60.1; 5.4
SECONDARY
Percentage of Subjects With a ≥ 1-grade Improvement on the Investigator's Assessment of CFL Severity at Maximum Smile on the 4-point FWS-A
85.1; 12.9
SECONDARY
Percentage of Subjects Reporting Their Global Change in Appearance as Very Much Improved or Much Improved Using the 7-point Subject's Global Assessment of Change in CFL (SGA-CFL)
54.4; 3.0
SECONDARY
Percentage of Subjects Assessing Their Age-related Facial Appearance as Looking Younger on the Self-Perception of Age (SPA) Questionnaire
53.9; 14.7
SECONDARY
Percentage of Subjects Achieving None or Mild on the Subject's Assessment of the Severity of Crow's Feet Lines (CFL) at Maximum Smile Using the Facial Wrinkle Scale-Asian (FWS-A)
60.8; 5.9

Summary

This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) compared with placebo in patients with moderate to severe crow's feet lines (lateral canthal lines).

Eligibility Criteria

Inclusion Criteria

-Moderate to severe Crow's Feet Lines.

Exclusion Criteria

  • Current or previous treatment with botulinum toxin of any serotype for any condition within the last year
  • Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis
  • Facial laser or light treatment, microdermabrasion or chemical peels within 3 months
  • Radio frequency laser treatments, phototherapy, blepharoplasty, brow-lift or related procedure, permanent make-up, oral retinoid therapy or treatment with non-permanent soft tissue fillers within 1 year
  • Any medium-depth or deep facial peels within 5 years
  • Periorbital surgery, face-lift, mid facial or periorbital treatment with permanent soft tissue fillers, synthetic implants or autologous fat transplant.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02195687). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search